瑞舒伐他汀对冠心病合并高脂血症患者血糖影响观察

Influence of Rosuvastatin on the Blood Sugar of Patients with Coronary Heart Disease Combined Hyperlipidemia

目的：考察冠心病合并高脂血症患者服用瑞舒伐他汀后对血糖的影响。方法：选择2012年1月1日至2014年10月31日收治的100例冠心病合并高脂血症患者作为研究对象，分为低剂量组（68例）和强化剂量组（32例），男58例，女42例，年龄40～76岁。低剂量组患者在常规治疗基础上服用瑞舒伐他汀（商品名：可定）10mg，强化剂量组则为瑞舒伐他汀剂量是20mg，余不变。观察两组治疗前后的体重指数（ BMI）、血糖和血脂指标的变化和观察期间的药物不良反应。结果：治疗12周后，两组LDL－C、TC及TG均有明显降低（P＜0．05），且强化剂量组血脂下降水平更低；强化剂量组治疗后FBG及HbA1c水平较治疗前略有上升，但两组治疗前后血糖指标均无显著变化。两组不良反应均为少数患者出现肝酶轻微升高，不影响后续治疗。结论：瑞舒伐他汀在降低血脂的同时对患者血糖代谢有良好的安全性，可应用于冠心病合并高脂血症患者，对属于发生心血管事件极高危的CAD患者人群，为使LDL－C达到＜1．8mmoL／L的目标值，部分患者可能需强化剂量（20mg／d）。

Objective：To investigate the influence of rosuvastatin on the blood sugar of patients with coronary heart disease （CHD） combined hyperlipidemia .Method：From Jan.2012 to Oct.2014, 100 cases of CHD combined hyperlipidemia in our hospital were divided into the low dose group （ 68 cases ） and strengthening dosage group （ 32 cases ） .Patients of low dose group were accepted the conventional basis 〈br〉 treatment combining with rosuvastatin （trade name：Crestor） 10mg, and strengthen dose group was just in-stead of rosuvastatin （20mg doses）.and then observed the change of body mass index （BMI）, blood sugar and blood lipids index after treatment and adverse drug reactions .Result：12 weeks after treatment , LDL-C, TC and TG in two groups were significantly decreased （P〈0.05）, blood lipid level in strengthen dose group was obviously lower than the low dose group .FBG and HbA1c level in strengthen dose group were slightly higher than the treatment before, but no significant statistical difference in the two groups （P〉0.05）.Con-clusion：Rosuvastatin can be used for patients with CHD combined hyperlipidemia , reducing blood lipid , with good security to glucose metabolism .In the patients of CAD with high risk of cardiovascular events ,the dose needs to add to 20mg per day in ordre to gain the aim of LDL -C 〈1.8 tendency /L.